Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery

Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the medical device maker could take a hit from the surging popularity of weight-loss drugs. Shares across the sector have tumbled in recent months on concerns that popular new GLP-1 drugs, like Novo Nordisk's Ozempic and Wegovy, approved to treat diabetes and weight loss, could carve into the market for bariatric surgery and devices used by diabetes patients, among others. However, Boston Scientific is unlikely to see any pressure in the third quarter or in the near-term from GLP-1s due to its very small bariatric exposure, and a longer-term impact to its heart devices is unclear, analysts have said.